Arcutis’ Roflumilast Foam Continues to Impress in Seb Derm
Roflumilast foam, 0.3% (Zoryve, Arcutis) bests vehicle in the treatment of seborrheic dermatitis, with 80% of individuals achieving Investigator Global Assessment (IGA) success and 51% of individuals reaching complete clearance at Week 8, according to new research published in the February 2024 issue of the Journal of American Academy of Dermatology. Zoryve foam was approved by […]